Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vupanorsen 80 mg Phase 1 cardiovascular agent study (Japan)
jRCT2080225294Phase 1Completed
- Start
- Jul 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of vupanorsen in cardiac morbidity. Started Jul 2020; status: completed.
02
Drugs
vupanorsen
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on jRCT2080225294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225294.